NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size

Cardiovascular Research

Volumn 101, Issue 2, 2014, Pages 220-228

  Bice, Justin S ^a   Keim, Yvonne ^b   Stasch, Johannes Peter ^b   Baxter, Gary F ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b BAYER PHARMA AG   (Germany)

Author keywords

cGMP; Ischaemia reperfusion; NO; SGC

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; GUANYLATE CYCLASE; TETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OCCLUSION; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART MUSCLE NECROSIS; HEART PROTECTION; LEFT CORONARY ARTERY; MALE; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RAT; REPERFUSION; STAINING; STIMULATION;

CGMP; ISCHAEMIA-REPERFUSION; NO; SGC;

ANIMALS; BENZOATES; BIPHENYL COMPOUNDS; CYCLIC GMP; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; GUANYLATE CYCLASE; HYDROCARBONS, FLUORINATED; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NECROSIS; NITRIC OXIDE; OXIDATION-REDUCTION; PYRAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SECOND MESSENGER SYSTEMS; TIME FACTORS;

EID: 84893109325     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt257     Document Type: Article

References (31)

1. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: Opportunities and obstacles for survival signaling. Brit J Pharmacol 2007;152:855-869
2. Burley DS, Baxter GF. B-type natriuretic peptide at early reperfusion limits infarct size in the rat isolated heart. Basic Res Cardiol 2007;102:529-541
3. Yang XM, Philipp S, Downey JM, Cohen MV. Atrial natriuretic peptide administered just prior to reperfusion limits infarction in rabbit hearts. Basic Res Cardiol 2006;101: 311-318
4. Ren B, Shen Y, Shao H, Qian J, Wu H, Jing H. Brain natriuretic peptide limits myocardial infarct size dependent of nitric oxide synthase in rats. Clin Chim Acta 2007;377:83-87
5. Yang X-M, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100:57-63
6. Gerzer R, Bohme E, Hofmann F, Schultz G. Soluble guanylate cyclase purified from bovine lung contains heme and copper. FEBS Lett 1981;132:71-74
7. Ignarro LJ, Degnan JN, Baricos WH, Kadowitz PJ,Wolin MS. Activation of purified guanylate cyclase by nitric oxide requires heme. Comparison of heme-deficient, heme-reconstituted and heme-containing forms of soluble enzyme from bovine lung. Biochim Biophys Acta 1982;718:49-59
8. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, Arun Kumar HS, Meurer S et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-2561
9. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:H1763-H1771
10. Roy B, Mo E, Vernon J, Garthwaite J. Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol 2008;153:1495-1504
11. Andelova E, Bartekova M, Pancza D, Styk J, Ravingerova T. The role of NO in ischemia / reperfusion injury in isolated rat heart. Gen Physiol Biophys 2005;24:411-426
12. Schindler U, Strobel H, Schonafinger K, LinzW, Lo?hn M, Martorana PA et al. Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 2006;69:1260-1268
13. Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vitro studies. Br J Pharmacol 2002;135:333-343
14. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410: 212-215
15. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vivo studies. Br J Pharmacol 2002;135:344-355
16. Becker E, Alonso-Alija C, Apeler H, Gerzer R, Minuth T, Pleibeta U et al. NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. BMC Pharmacol 2001;1:13
17. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C et al. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 1999;127:195-203
18. Straub A, Benet-Buckholz J, Frode R, Kern A, Kohlsdorfer C, Schmitt P et al. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg Med Chem 2002;10:1711-1717
19. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001; 11:781-784
20. Cohen MV, Yang X-M, Liu Y, Solenkova NV, Downey JM. Cardioprotective PKG-independent NO signaling at reperfusion. Am J Physiol-Heart C 2010;299: H2028-H2036
21. Ovize M, Baxter GF,Di Lisa F, Ferdinandy Pt, Garcia-Dorado D, Hausenloy DJ et al. Postconditioning and protection from reperfusion injury: Where do we stand? Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010;87:406-423
22. D'Souza SP, Yellon DM, Martin C, Schulz R, Heusch G, Onody A et al. B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol 2003;284:H1592-H1600
23. Krieg T, Liu Y, Rutz T, Methner C, Yang XM, Dost T et al. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. Eur Heart J 2009;30:1607-1613
24. Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA et al. Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: Role of hydrogen sulfide. Am J Physiol-Heart C 2012;302:H1347-H1354
25. Schmidt P, Schramm M, Schroder H, Stasch JP. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur J Pharmacol 2003;468:167-174
26. Toque HA, Mó nica FZT, Morganti RP, De Nucci G, Antunes E. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle. Eur J Pharmacol 2010;645:158-164
27. Keefer LK, Nims RW, Davies KM, Wink DA. 'NONOates' (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: Convenient nitric oxide dosage forms. Methods Enzymol 1996;268:281-293
28. Stangherlin A, Zaccolo M. cGMP-cAMP interplay in cardiac myocytes: A local affair with far-reaching consequences for heart function. Biochem Soc Trans 2012;40:11-14
29. Castro LR, Schittl J, Fischmeister R. Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes. Circ Res 2010;107:1232-1240
30. Hoffmann LS, Schmidt PM, Keim Y, Hoffmann C, Schmidt HHHW, Stasch J-P. Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. PLoS One 2011;6:e23596
31. Gori T, Parker JD. The puzzle of nitrate tolerance: Pieces smaller than we thought? Circulation 2002;106:2404-2408